基于肝门静脉注射肿瘤细胞的新型进展期肝脏肿瘤动物模型的建立

Constructing an intrahepatic model of advanced liver cancer by injecting cancer cells through the hepatic portal vein

目的利用肝门静脉注射肿瘤细胞的方法,建立新型进展期肝脏肿瘤(肝细胞癌、结直肠癌肝转移、乳腺癌肝转移以及非小细胞肺癌肝转移)的动物模型。方法培养获得人肝细胞癌MHCC97-H、人结直肠癌SW480、人非小细胞肺癌A549以及人三阴性乳腺癌MDA-MB-231等细胞系,将这些恶性肿瘤细胞经由BALB/c裸小鼠肝门静脉注入肝脏,经3~4周生长后进行PET/CT检测:尾静脉注射约200μCi核素探针18F-FDG,30~40 min后对BALB/c裸小鼠进行PET/CT检测。在此基础上,收集动物获取肝脏进行拍照,确定BALB/c裸小鼠肝脏上的肿瘤病灶。结果 MHCC97-H、SW480、A549以及MDA-MB-231等细胞均能够在BALB/c裸小鼠肝脏形成多发、弥散的肿瘤病灶。肿瘤细胞在裸小鼠肝脏原位的生长可以使用PET/CT检测。SW480、MDA-MB-231以及A549细胞形成的病灶,其PET/CT检测信号弱于MHCC97-H细胞。结论成功获得了新型进展期肝脏肿瘤动物模型,为进展期肝脏肿瘤相关药物筛选奠定了坚实基础。

Objective To construct an intrahepatic model of advanced liver cancer(hepatocellular carcinoma,colorectal cancer liver metastasis,breast cancer liver metastasis,non-small cell lung cancer liver metastasis)by injecting cancer cells through the hepatic portal vein.Methods MHCC97-H,a highly aggressive cell line of hepatocellular carcinoma;SW480,a metastatic colorectal cancer cell line;MDA-MB-231,a human triple-negative breast cancer cell line;or A549,a non-small cell lung cancer cell line,was cultured and seeded into the liver of BALB/c nude mice by injecting cancer cells through the hepatic portal vein.After 3-4 weeks of growth,mice were analyzed by PET/CT screening.Mice were injected with approximately 200μCi nuclide probe 18 F-FDG through the tail vein.The BALB/c nude mice were analyzed by PET/CT screening after 30-40 min.The mice were then collected,and their livers were obtained and photographed to determine the presence of tumor nodules on the liver of BALB/c nude mice.Results MHCC97-H,A549,SW480,or MDA-MB-231 cells grew and multiple diffuse tumor nodules formed in the nude mouse livers.Nodules in the nude mouse livers formed by cancer cells could be identified by PET/CT screening;the PET/CT intensity of nodules formed after A549,SW480,or MDA-MB-231 cell injection was weaker than that of MHCC97-H cells.Conclusions An intrahepatic tumor animal model of advanced liver cancer has been successfully constructed by injecting cancer cells through the hepatic portal vein.This is a promising model for research on liver cancer or antitumor drugs.